无锡祥生医疗科技股份有限公司（以下简称"公司"）第二届监事会任期即 将届满，根据《公司法》《上海证券交易所科创板股票上市规则》等法律、法规、 规范性文件及《公司章程》的规定，公司于 2023 年 8 月 8 日召开职工代表大会， 选举胡耀新女士担任公司第三届监事会职工代表监事，职工代表监事简历详见附 件。 公司第三届监事会由三名监事组成，本次职工代表大会选举产生的职工代表 监事，将与公司股东大会选举产生的两名股东代表监事共同组成公司第三届监事 会，任期三年，与第三届监事会任期一致。 特此公告。 证券代码：688358 证券简称：祥生医疗 公告编号：2023-021 无锡祥生医疗科技股份有限公司 关于选举职工代表监事的公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 无锡祥生医疗科技股份有限公司 第三届监事会职工代表监事简历 胡耀新，女，1969 年出生，中国国籍，无境外永久居留权。毕业于电仪职 大电子技术应用专业，专科学历。1996 年 1 月至今，就职于本公司探头生产经 理职务；2007 年 12 月至今，兼任公司工 ...

证券代码：688358 证券简称：祥生医疗 公告编号：2023-022 无锡祥生医疗科技股份有限公司 第二届监事会第十七次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、监事会会议召开情况 无锡祥生医疗科技股份有限公司（以下简称"公司"）第二届监事会第十七次 会议于 2023 年 8 月 9 日以现场结合通讯表决的方式召开，公司于 2023 年 8 月 3 日以邮件及通讯方式向全体监事发出召开本次会议的通知，与会的各位监事已知 悉与所议事项相关的必要信息。会议应出席监事 3 人，实际到会监事 3 人，会议 的召集和召开程序符合《中华人民共和国公司法》（以下简称"《公司法》"） 等法律、法规、部门规章以及《无锡祥生医疗科技股份有限公司章程》（以下简 称"《公司章程》"）的有关规定，作出的决议合法、有效。 二、监事会会议审议情况 1. 审议通过《关于监事会换届暨选举第三届监事会股东代表监事的议案》 经审查，张勇、龚栋梁符合《公司法》等相关法律、法规和规范性文件对 监事任职资格的要求，公司监事会同意提名张勇、龚 ...

证券代码：688358 证券简称：祥生医疗 公告编号：2023-023 无锡祥生医疗科技股份有限公司 关于召开 2023 年第一次临时股东大会的通知 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 一、 召开会议的基本情况 （一） 股东大会类型和届次 （六） 融资融券、转融通、约定购回业务账户和沪股通投资者的投票程序 2023 年第一次临时股东大会 召开日期时间：2023 年 8 月 25 日 14 点 00 分 召开地点：无锡市新吴区新辉环路 9 号 公司一楼会议室 （五） 网络投票的系统、起止日期和投票时间。 网络投票系统：上海证券交易所股东大会网络投票系统 网络投票起止时间：自 2023 年 8 月 25 日 至 2023 年 8 月 25 日 采用上海证券交易所网络投票系统，通过交易系统投票平台的投票时间为股 东大会召开当日的交易时间段，即 9:15-9:25,9:30-11:30，13:00-15:00；通过互联 股东大会召开日期：2023年8月25日 本次股东大会采用的网络投票系统：上海证券交易所 ...

无锡祥生医疗科技股份有限公司董事会现提名李寿喜为无锡祥生医疗科技 股份有限公司第三届董事会独立董事候选人,并已充分了解被提名人职业专长、 教育背景、工作经历、兼任职务等情况。被提名人已书面同意出任无锡祥生医疗 科技股份有限公司第三届董事会独立董事候选人。提名人认为,被提名人具备独 立董事任职资格,与无锡祥生医疗科技股份有限公司之间不存在任何影响其独立 性的关系,具体声明如下: 独立董事提名人声明 一、被提名人具备上市公司运作的基本知识,熟悉相关法律、行政法规、规 章及其他规范性文件,具有五年以上法律、经济、财务、管理或者其他履行独立 董事职责所必需的工作经验,并已根据相关规定取得独立董事资格证书。 (二)《公务员法》关于公务员兼任职务的规定; (三)中央纪委、中央组织部《关于规范中管干部辞去公职或者退(离)休 后担任上市公司、基金管理公司独立董事、独立监事的通知》的规定; (四)中央纪委、教育部、监察部《关于加强高等学校反腐倡廉建设的意见》 关于高校领导班子成员兼任职务的规定; (五)中国保监会《保险公司独立董事管理暂行办法》的规定; (六)其他法律、行政法规和部门规章规定的情形。 三、被提名人具备独立性,不 ...

二、《关于董事会换届暨选举第三届董事会独立董事的议案》 经过对公司第三届董事会独立董事候选人的背景、工作经历的了解，我们认 为公司第三届董事会独立董事候选人未持有公司股份，与公司控股股东、实际控 制人及其他董事候选人、监事候选人之间不存在关联关系，不存在《公司法》规 定的不得担任公司董事的情形，未受到中国证券监督管理委员会的行政处罚或交 易所惩戒，不属于相关法律法规、部门规章、规范性文件等规定的不得担任公司 独立董事的情形。 无锡祥生医疗科技股份有限公司独立董事 关于第二届董事会第十九次会议相关议案的独立意见 无锡祥生医疗科技股份有限公司（以下简称"公司"）于 2023 年 8 月 9 日召 开第二届董事会第十九次会议（以下简称"会议"）。根据《中华人民共和国公司 法》等法律、法规及《无锡祥生医疗科技股份有限公司章程》的相关规定，我们 作为公司的独立董事，在认真审阅有关文件资料后，对公司第二届董事会第十九 次会议相关议案，发表如下独立意见： 一、《关于董事会换届暨选举第三届董事会非独立董事的议案》 经过对公司第三届董事会非独立董事候选人的背景、工作经历的了解，我们 认为第三届董事会非独立董事候选人不存在《公司 ...

证券代码：688358 证券简称：祥生医疗 公告编号：2023-015 无锡祥生医疗科技股份有限公司 关于召开 2022 年度医疗设备专场集体业绩说明会 暨 2023 年第一季度业绩说明会的公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示 无锡祥生医疗科技股份有限公司（以下简称"公司"）已于2023年4月19日在 上海证券交易所网站（www.sse.com.cn）披露公司《2023年年度报告》和《2023 年第一季度报告》，为便于广大投资者更全面深入地了解公司2023年度以及2023 年第一季度经营成果、财务状况，公司参与了由上海证券交易所主办的2022年度 医疗设备专场集体业绩说明会，计划于2023年6月16日14:00-15:00召开2022年度 医疗设备专场集体业绩说明会暨2023年第一季度业绩说明会，就投资者关心的问 题进行交流。 一、 说明会类型 本次说明会以视频结合网络互动方式召开，公司将针对 2022 年度及 2023 年第一季度经营成果及财务指标的具体情况与投资者进行互动交流和沟通，在信 息 ...

Financial Performance - The company's operating revenue for 2022 was ¥380,843,344.13, a decrease of 4.27% compared to ¥397,811,875.09 in 2021[19]. - The net profit attributable to shareholders for 2022 was ¥105,842,831.46, down 5.89% from ¥112,472,408.71 in the previous year[19]. - The net profit after deducting non-recurring gains and losses increased by 25.87% to ¥98,440,015.40 in 2022 from ¥78,207,777.43 in 2021[19]. - The net cash flow from operating activities for 2022 was ¥63,741,276.37, representing a significant increase of 59.51% compared to ¥39,960,965.16 in 2021[19]. - The total assets at the end of 2022 were ¥1,513,926,604.17, an increase of 8.29% from ¥1,398,069,571.61 at the end of 2021[19]. - The net assets attributable to shareholders increased by 5.45% to ¥1,313,508,192.90 at the end of 2022 from ¥1,245,581,541.50 at the end of 2021[19]. - The weighted average return on equity decreased to 8.30%, down from 9.27% in the previous year[21]. - The gross profit margin improved to 59.28%, up by 2.99 percentage points from the previous year[98]. - The company achieved a net loss of ¥392.78 million for Xiangsheng Technology, with total assets of ¥681.20 million[118]. Research and Development - The company increased its R&D investment by 7.74% year-on-year, reaching CNY 77.88 million, which accounted for a record high of 20.45% of total operating revenue[30]. - The company registered 31 new patents in 2022, including 20 invention patents, and submitted 75 new intellectual property applications[30]. - The company has a comprehensive R&D model with centers in China and the U.S., focusing on core technologies from material research to system design[40]. - The company has made significant breakthroughs in specialized ultrasound technologies, particularly in breast and vascular access imaging, as well as in artificial intelligence and remote diagnosis[66]. - The company is focusing on breakthroughs in high-end imaging technology and probe technology to enhance its competitive edge in the ultrasound sector[57]. - The company has developed a range of proprietary technologies, including 1-3 composite material transducer technology and high-performance single crystal material technology, to improve probe efficiency and sensitivity[71]. - The company has established a proprietary algorithm for real-time ultrasound image transmission, ensuring high-quality imaging even under low bandwidth conditions, positioning itself as a leader in the domestic market[68]. Market Strategy and Expansion - Future strategies include market expansion and potential mergers and acquisitions to enhance product offerings and market presence[18]. - The company has expanded its product coverage significantly, with products now reaching over 30% of tertiary hospitals and being sold in more than 100 countries and regions[36][37]. - The company aims to focus on high-end ultrasound technology, portable ultrasound devices, and ultrasound artificial intelligence as part of its strategic development goals[121]. - The company plans to enhance brand building and market penetration through regional activities and new media promotion strategies[123]. - Market expansion efforts led to a 30% increase in international sales, with significant growth in the European market[134]. Corporate Governance - The company maintains a governance structure that ensures independence and coordination among the board of directors, supervisory board, and management[130]. - The company has a robust governance framework that adheres to the regulations set forth by the China Securities Regulatory Commission[130]. - The company has not faced any major issues regarding independence or operational autonomy from its controlling shareholder[130]. - The company has established a compensation and assessment committee responsible for formulating remuneration plans for senior management personnel[140]. - The company held four shareholder meetings during the reporting period, all of which complied with relevant laws and regulations, and the resolutions were legally valid[129]. Social Responsibility and Environmental Initiatives - The company actively participates in social responsibility initiatives, contributing a total of 21.46 million CNY, including 0.88 million CNY in cash donations and 20.58 million CNY in material donations[179]. - The company emphasizes environmental protection, having implemented measures to prevent pollution and ensure compliance with local environmental standards, with no administrative penalties received for environmental issues[173]. - The company has integrated green energy-saving design concepts into its product development, promoting low-power consumption products across its entire product line[177]. - The company has implemented strict waste management practices, including recycling and proper disposal of hazardous materials, to minimize environmental impact[175]. Dividend and Shareholder Information - The company plans to distribute a cash dividend of 7 RMB per 10 shares, totaling approximately 78.49 million RMB, which represents 74.15% of the net profit attributable to shareholders for 2022[5]. - The total share capital as of December 31, 2022, was 112,124,537 shares, which will be the basis for the dividend distribution[156]. - The cash dividend distribution plan is subject to approval at the shareholders' meeting[156]. - The company has a clear and defined dividend policy that complies with its articles of association and shareholder resolutions[157]. Risks and Challenges - The company has detailed risk factors that may affect its operations in the management discussion and analysis section of the report[4]. - The company faces risks related to product development failures and potential technology leaks, which could impact its competitive position in the market[86]. - The company is exposed to financial risks, including potential increases in bad debts and inventory write-downs due to market fluctuations[91]. - The company faced risks related to new product registration, particularly in the context of evolving regulatory environments[90].

Financial Performance - The company's operating revenue for Q1 2023 was CNY 165,154,528.52, representing a year-on-year increase of 64.55%[5] - The net profit attributable to shareholders was CNY 52,513,874.14, reflecting a growth of 111.31% compared to the same period last year[6] - Basic earnings per share (EPS) stood at CNY 0.47, up by 113.64% from the previous year[6] - Total operating revenue for Q1 2023 reached RMB 165,154,528.52, a 64.6% increase from RMB 100,367,467.51 in Q1 2022[22] - Net profit for Q1 2023 was RMB 52,513,874.14, representing a 111.1% increase compared to RMB 24,852,007.66 in Q1 2022[23] - The company reported a total profit of RMB 59,674,856.98 for Q1 2023, an increase from RMB 29,011,776.30 in Q1 2022[23] Cash Flow and Liquidity - The net cash flow from operating activities reached CNY 3,297,962.45, an increase of 133.51% year-on-year[6] - Cash flow from operating activities generated a net amount of RMB 3,297,962.45, a significant improvement from a net outflow of RMB 9,842,847.19 in Q1 2022[26] - Cash and cash equivalents at the end of Q1 2023 totaled RMB 476,375,439.25, down from RMB 734,839,296.15 at the end of Q1 2022[27] - Investment activities generated a net cash inflow of RMB 35,595,811.20 in Q1 2023, compared to RMB 307,397,052.00 in Q1 2022[27] Assets and Liabilities - Total assets at the end of the reporting period were CNY 1,591,043,073.39, a 5.09% increase from the end of the previous year[6] - The company's total equity as of March 31, 2023, was CNY 1,367,393,741.24, up from CNY 1,313,508,192.90, marking an increase of approximately 4.1%[19] - The total current liabilities rose to CNY 212,505,799.94, compared to CNY 188,470,568.81 at the end of 2022, reflecting an increase of about 12.7%[18] - The total liabilities increased to CNY 223,649,332.15 from CNY 200,418,411.27, reflecting an increase of about 11.6%[19] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 5,354[13] - The top shareholder, Wuxi Xiangsheng Investment Co., Ltd., holds 40.46% of the shares, totaling 45,360,000 shares[13] Research and Development - Research and development (R&D) expenses totaled CNY 19,931,113.52, accounting for 12.07% of operating revenue, a decrease of 6.83 percentage points[6] - Research and development expenses for Q1 2023 were RMB 19,931,113.52, slightly up from RMB 18,967,543.27 in Q1 2022[22] Other Financial Metrics - The company experienced a 902.82% increase in financial expenses, mainly due to foreign exchange losses[11] - The company reported a foreign exchange loss of RMB 5,789,980.73 in Q1 2023, compared to a loss of RMB 1,209,622.83 in Q1 2022[27] - Accounts receivable increased by 128.36%, primarily due to the growth in domestic and international sales revenue[10] - Accounts receivable increased significantly to CNY 213,565,566.53 from CNY 93,521,760.48, representing a growth of approximately 128%[17] - The company's inventory decreased to CNY 161,833,169.93 from CNY 196,957,143.80, a decline of approximately 17.8%[17] - The non-current assets totaled CNY 178,752,164.59, slightly up from CNY 175,100,762.63, indicating a growth of about 1.5%[18] - The company reported a significant increase in other non-current assets to CNY 8,411,230.63 from CNY 5,500,476.00, representing a growth of approximately 52.1%[18] - The company's retained earnings rose to CNY 294,240,893.63 from CNY 241,727,019.49, an increase of approximately 21.7%[19]

无锡祥生医疗科技股份有限公司 投资者关系活动记录表 证券代码：688358 证券简称：祥生医疗 编号：2022-003 无锡祥生医疗科技股份有限公司 投资者关系活动记录表 | --- | --- | --- | --- | |----------------------|-------|--------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ...

无锡祥生医疗科技股份有限公司 投资者关系活动记录表 证券代码：688358 证券简称：祥生医疗 编号：2022-004 无锡祥生医疗科技股份有限公司 投资者关系活动记录表 | --- | --- | --- | --- | |--------------------|-------|---------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ ...